The association between self-reported cataracts and St. John's Wort

Current Eye Research

Volumn 34, Issue 10, 2009, Pages 863-866

  Booth III, John N ^a   McGwin Jr , Gerald ^b  

^a School of Nursing and Mailman

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cataract; Herbal treatments; Population based sample; St. John's Wort

Indexed keywords

HERBACEOUS AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CATARACT; CONTROLLED STUDY; FEMALE; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SELF REPORT; SEX RATIO;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CATARACT; DEPRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERICUM; LENS, CRYSTALLINE; MALE; MIDDLE AGED; PERYLENE; QUESTIONNAIRES; SEX FACTORS;

EID: 70449509696     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903144692     Document Type: Article

References (18)

1. poldinger W. History of St. John's wort. Praxis. 2000;89:2102-2109.
2. U.S. Department of Agriculture. St. John's Wort. Fact Sheet No. 18;2001:1-6. Available at www.sfp.forprod.vt.edu/factsheets/wort.pdf.
3. Kubin A, Wierrani F, Burner U, Alth G, Grunberger W. Hypericin-The facts about a controversial agent. Curr Pharm Des. 2005;11:233-253.
4. Barnes J, Anderson LA, Phillipson JD. St. John's wort (Hypericum perforatum L.): A review of its chemistry, pharmacology, and clinical properties. J Pharm Pharmacol. 2001;53:583-600.
5. Butterweck V, Schmidt M. St. John's wort: Role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr. 2007;157:356-361.
6. Calapai G, Crupi A, Firenzuoli F, Inferrera G, Squadrito F, Parisi A, DeSarro G, Caputi A. Serotonin, norepinephrine, and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry. 2001;34:45-49.
7. Muller WE, Rolli M, Schafer S, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997;30: 102-107.
8. Wonnemann M, Singer A, Muller WE. Inhibition of synaptosomal uptake of 3H-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's wort: The role of amiloride-sensitive sodium conductive pathways. Pharmacopsychiatry. 2001;34:S148-S151.
9. Schulz V. Clinical trials with Hypericum extracts in patients with depression-Results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine. 2002; 9:468-474.
10. Sgarbossa A, Angelini N, Gioffre D, Youssef T, Lenci F, Roberts FE. The uptake, location, and fluorescence of hypericin in bovine intact lens. Curr Eye Res. 2000;21:597-601.
11. Wahlman J, Hirst M, Roberts JE, Prickett CD, Trevitchick JR. Focal length variability and protein leakage as tools for measuring photooxidative damage to the lens. Photochem Photobiol. 2003;78:88-92.
12. He YY, Chignell CF, Miller DS, Andley UP, Roberts JE. Phototoxicity in human lens epithelial cells promoted by St. John's Wort. Photochem Photobiol. 2004;80: 583-586.
13. Roberts JE. Screening for ocular phototoxicity. Int J Toxicol. 2002;21:491-500.
14. Schey KL, Patat S, Chignell CF, Datillo M, Wang RH, Roberts JE. Photooxidation of lens a-crystallin by hypericin (active ingredient in St. John's wort). Photochem Photobiol. 2000;72:200-203.
15. Harris MS, Sakamoto T, Kimura H, He S, Spee C, Gopalakrishna R, Gundimeda U, Yoo JS, Hinton DR, Ryan SJ. Hypericin inhibits cell growth and induces apoptosis in retinal pigment epithelial cells: Possible involvement of protein kinase. Curr Eye Res. 1996;15:255-262.
16. Boerrigter RM, Siertsema JV, Kema IP. Serotonin (5-HT) and the rat's eye. Some pilot studies. Doc Ophthalmol. 1992;82:141-150.
17. Purves D, Augustine GJ, Fitzpatrick D, Lamantia AS, McNamara JO, Williams SM, eds. Neuroscience. Sunderland, MA: Sinauer Associates; 2004.
18. Christen WG, Glynn RJ, Seddon JM, Manson JE, Buring JE, Hennekens CH. Confirmation of self-reported cataract in the Physicians' Health Study. Ophthalmic Epidemiol. 1994;1:85-91.